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Follicular helper T (Tfh) cells are required for the
establishment of T-dependent B cell memory and
high affinity antibody-secreting cells. We have re-
vealed herein opposing roles for signal transducer
and activator of transcription 3 (STAT3) and type I
interferon (IFN) signaling in the differentiation of Tfh
cells following viral infection. STAT3-deficient CD4+
T cells had a profound defect in Tfh cell differentia-
tion, accompanied by decreased germinal center
(GC) B cells and antigen-specific antibody produc-
tion during acute infection with lymphocytic cho-
riomeningitis virus. STAT3-deficient Tfh cells had
strikingly increased expression of a number of
IFN-inducible genes, in addition to enhanced T-bet
synthesis, thus adopting a T helper 1 (Th1) cell-like
effector phenotype. Conversely, IFN-ab receptor
blockade restored Tfh and GC B cell phenotypes in
mice containing STAT3-deficient CD4+ T cells. These
data suggest mutually repressive roles for STAT3
and type I IFN signaling pathways in the differentia-
tion of Tfh cells following viral infection.
INTRODUCTION
Follicular T helper (Tfh) cells are a subset of CD4+ T cells required
for the T-dependent germinal center (GC) response leading to
the production of antigen-specific memory B and plasma cells
(Crotty, 2011; McHeyzer-Williams et al., 2012). Proper regulation
of Tfh cell differentiation in secondary lymphoid organs (SLOs) is
critical for controlled immune function. Poor response of these
cells is associated with a defective GC reaction (Johnston
et al., 2009; Nurieva et al., 2009; Yu et al., 2009), whereas their
overabundance can lead to pathogenic autoantibody production
and autoimmune disease (Linterman et al., 2009; Vinuesa et al.,
2005). Upregulation of B cell lymphoma 6 (Bcl6), the canonical
Tfh cell transcription factor, and downregulation of its tran-
scriptional repressor B-lymphocyte-induced maturation protein
1 (Blimp-1), are required for initiation of the Tfh cell development
program (Johnston et al., 2009; Nurieva et al., 2009; Yu et al.,2009). Expression of Bcl6, concomitant with downregulation
of the chemokine receptor CCR7 and P-selectin glycoprotein
ligand-1 (PGSL-1) in concert with CXCR5 upregulation, enables
Tfh cells to emigrate from the T cell zone of SLOs to the B cell fol-
licle where they can promote GC reactions (Haynes et al., 2007;
Marshall et al., 2011; Poholek et al., 2010). Bcl6 upregulation
in nascent Tfh cells occurs in a two-step process dependent
upon inducible T cell costimulator (ICOS) signaling via ICOS-
ligand (ICOS-L), delivered first by dendritic cells in the T cell
zone of SLOs, and second by interactions with B cells at the
T-B border in the spleen and interfollicular regions of lymph no-
des (Choi et al., 2013; Coffey et al., 2009; Kerfoot et al., 2011).
Previous work has suggested a role for the inflammatorymilieu
in promoting the Tfh cell phenotype, particularly those cytokines
that are known to signal through signal transducer and activator
of transcription 3 (STAT3). For example, the cytokines inter-
leukin-6 (IL-6), IL-21, and IL-27 have been implicated in Tfh cell
development, albeit with differing roles. IL-6 is required for devel-
opment of Tfh cells early following viral challenge (Choi et al.,
2013), while also promoting their maintenance later in chronic
viral infections (Harker et al., 2011), with IL-27 needed for their
maintenance upon protein immunization (Batten et al., 2010).
IL-21 has also been reported to be important for Tfh cell differen-
tiation (Nurieva et al., 2008; Vogelzang et al., 2008), although
such a role has not been universally found, a difference perhaps
reflecting mode of immunization (Linterman et al., 2010; Zotos
et al., 2010). In the absence of IL-6, IL-21 is more important
in later stages following protein immunization or viral challenge
(Eto et al., 2011; Karnowski et al., 2012), yet it is not required
early in Tfh cell differentiation (Choi et al., 2013). As would be
expected from these results, STAT3 has been reported to be
required for the development of CXCR5+ CD4+ T cells, following
challenge with the antigen KLH in complete Freund’s adjuvant
and their subsequent function in promoting the development
of peanut agglutinin+ (PNA+) GC B cells (Nurieva et al., 2008).
Human subjects with dominant-negative mutations in STAT3
also display reduced numbers of CXCR5+ circulating CD4+
T cells, related to Tfh cells in SLOs further suggesting the poten-
tial importance of this signaling pathway in Tfh cell differentiation
(Ma et al., 2012). Yet, work using adoptive transfers of viral-spe-
cific T cell receptor (TCR) transgenic CD4+ T cells reported a
requirement for STAT3 in Tfh cell development only within the
first 48 hr following viral infection, with normal Tfh cell differenti-
ation ensuing by 3 days after infection (Choi et al., 2013). ThisImmunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc. 367
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STAT3 and Type I IFNs in Tfh Cell Differentiationfinding is inconsistent with the broader roles of STAT3 cytokines
in Tfh cell development and maintenance.
Here, we have demonstrated a critical role for STAT3 in Tfh cell
development and function following acute viral infection. STAT3
expression in CD4+ T cells is required for their differentiation into
Tfh cells and promotion of GCB cell development and virus-spe-
cific antibody responses. We also identify a role for STAT3 in
downmodulating type I interferon (IFN) signaling, as STAT3-defi-
cient Tfh cells display a marked increase in Th1 cell-associated
and IFN-inducible transcripts. Accordingly, suppression of type
I IFN signaling by antibody blockade of the IFN-ab receptor pro-
moted Tfh cell differentiation in wild-type (WT) mice and mice
containing STAT3-deficient CD4+ T cells. The treatment also
rescued the GC and pathogen-specific antibody defect found
in the STAT3 mutant mice. This effect was specific to type I
IFNs, as blockade of IFN-g did not substantially alter Tfh cell per-
centages, nor affected GC B cell percentages after infection.
These findings demonstrate the importance of STAT3 and the
STAT3-activating cytokines in promoting Tfh cell differentiation
and function during viral infection, and furthermore, reveal con-
trasting roles for STAT3 and type I IFNs in determining the bal-
ance between Tfh and Th1 cell differentiation.
RESULTS
Mice Containing STAT3-Deficient CD4+ T Cells Have a
Reduction in Tfh Cell Differentiation and Impaired GC
Formation
Previous work using an antigen-adjuvant system demonstrated
that STAT3 has a T cell-intrinsic effect on the development of
CD4+ CXCR5hi cells and the promotion of GC B cell differentia-
tion (Nurieva et al., 2008). However, its role in Tfh cell develop-
ment and function following viral infection appears limited to
the first 2 days following challenge (Choi et al., 2013), an unex-
pected finding given that multiple STAT3-dependent cytokines
have been implicated in Tfh cell differentiation and continue
to be produced after day 3 of infection (Batten et al., 2010;
Eto et al., 2011). To address this issue, we ablated STAT3
from all CD4+ T cells by breeding Stat3fl/fl mice to Cd4cre mice
(Stat3fl/flCd4cre mice; abbreviated Stat3/ in the Figures)
(Schmidt-Supprian and Rajewsky, 2007; Welte et al., 2003;
Wolfer et al., 2001), and infected them with the Armstrong strain
of lymphocytic choriomeningitis virus (LCMV). Stat3fl/fl cre-nega-
tive littermates were used as controls and are designated as WT
for simplicity. At 8 days postinfection (dpi) we observed similar
frequencies of LCMV GP66-specific CD4
+ CD44+ T cells in
both Stat3fl/flCd4cre and WT littermate control mice despite
differences in splenocyte numbers (see Figures S1A and S1B
available online). Next, we compared the phenotypes of CD4+
Th1 and Tfh cells that formed in Stat3fl/flCd4cre and WT CD4+
T cells that have been previously characterized during LCMV
infection (Hale et al., 2013; Marshall et al., 2011). Increased
expression of PSGL-1 and Ly6C and decreased expression of
the chemokine receptor CXCR5 helped to distinguish Th1 cells
that expressed high amounts of T-bet, IFN-g, and granzyme B
and were localized in the red pulp (Figure 1A, red gates). Another
subset of PSGL-1hi Ly6Clo cells were mostly localized in the
T cell zone and expressed lower amounts of T-bet and IFN-g;
compared to the PSGL-1hi Ly6Chi cells, some of these cells368 Immunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc.also expressed CXCR5 (Figure 1A, blue gates) (Hale et al.,
2013; Marshall et al., 2011). Conversely, decreased expression
of Ly6C and PSGL-1 and increased expression of CXCR5 distin-
guished Tfh cells (Figures 1A; see Figure S1A available online,
green gates) (Hale et al., 2013; Marshall et al., 2011). Notably,
all PSGL-1lo cells expressed CXCR5, supporting previous evi-
dence that these cells are follicular T cells (Figure S1A) (Poholek
et al., 2010). Compared to the WT CD44+ or GP66-specific CD4
+
T cells, the Stat3fl/flCd4cre cells displayed a reduction in the pro-
portion and numbers of GP66
+ and polyclonal Ly6clo PSGL-1lo
cells and Ly6clo PSGL-1lo CXCR5hi Tfh cells at 8 dpi (Figures
1A–1E; Figures S1A and S1C–S1E). The mean fluorescence in-
tensities (MFI) of CXCR5 in the polyclonal and GP66
+ Ly6clo
PSGL-1lo populations were also reduced in cells from the
Stat3fl/flCd4cre mice compared to WT littermates (Figures S1F
and S1G). In association with a reduction in Ly6clo PSGL-1lo
CXCR5hi Tfh cells in Stat3fl/flCd4cre mice, GC B cells observed
by flow cytometry were considerably reduced at 8 dpi compared
to the WT mice (Figures 1F–1H). These findings were further
corroborated by confocal microscopy, which revealed that
mice with STAT3-deficient CD4+ T cells have fewer GCs per B
cell follicle (Figures 1I and 1J). The large reduction in GC B cells
seemed disproportionate to the diminution of Tfh cells, so we
analyzed the deletion efficiency ofStat3 fromCD4+ T cells versus
B cells, finding 97% deletion in CD4+ T cells, with none in B cells
(Figure S1H). A similar impairment in Tfh cell differentiation and
GC B cell responses was observed at 14 dpi (Figures S2A–
S2H). Thus, STAT3 activity in CD4+ T cells is critical for formation
of Tfh cells and activation of GC responses during viral infection.
Stat3fl/flCd4cre Mice Fail to Promote Robust Isotype-
Switched LCMV-Specific Antibody Production
With the defect in GC formation in the Stat3fl/flCd4cre mice, we
wondered whether early plasmablast responses were also
affected. These occur in extrafollicular regions of SLOs, before
highly affinity matured and isotype switched B cells exit the GC
(Zotos et al., 2010). The plasmablast response to LCMV infection
was analyzed with ELISAs to measure the generation of antigen-
specific antibodies in the serum at 8 dpi.We found that there was
a significant decrease in LCMV-specific immunoglobulin M (IgM)
and IgG in theStat3fl/flCd4cremice, compared toWTanimals (Fig-
ures 2A and 2B). By day 14 dpi, IgM responses were rescued,
whereas IgG responses remained hindered, suggesting that
LCMV-specific plasmablasts and plasma cells were either de-
layed or reduced in class-switch recombination to IgG (Figures
2Cand2D).Wealso found that IgG2a antibodieswere decreased
at 14 dpi, although this decrease was not significant (Figure 2E).
These data show there is a significant defect in the IgG antibody
response following LCMV infection of Stat3fl/flCd4cre mice.
STAT3-Deficient TfhCells Phenotypically Resemble Th1
Cells
We next examined the effects of STAT3-deficiency on Tfh cell
properties such as Bcl6 expression and IL-21 production, a Tfh
cell-producing cytokine that promotes GC longevity, B cell sur-
vival (Linterman et al., 2010; Zotos et al., 2010), and class switch
recombination to IgG1 (Ozaki et al., 2002). Bcl6 protein was
significantly decreased at 5 dpi (Figures 3A and 3B); however,
we found no differences at 8 dpi (data not shown). We also
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Figure 1. Stat3fl/flCd4cre Mice Have an Impaired Tfh Cell Response following Acute Viral Infection
(A and B) Flow cytometry plots of CD44+ (A) and GP66
+ LCMV epitope-specific (B) CD4+CD44+ T cells gated on Ly6c and PSGL-1. Th1 terminal effector
precursors are Ly6chi PSGL-1hi cells (red), Th1 central memory precursors are Ly6clo PSGL-1hi (blue), and Tfh cells are Ly6clo PSGL-1lo (green).
(C) Population distribution of terminal effector precursors, central memory precursors, and Tfh cells based on Ly6c and PSGL-1, gating as in (A).
(D and E) GP66-specific Tfh cell percentages (D) and numbers (E), gated as Ly6c
lo PSGL-1lo CXCR5hi.
(F–H) Flow cytometry plots (F), percentages (G), and numbers (H) of GC B cells, gated as B220+ IgDlo CD95hi GL-7+.
(I) Immunohistochemistry of spleen sections, identifying GCs with anti-PNA (red), anti-IgD (green), and anti-CD4 (blue). Scale bar represents 25 mm.
(J) Quantification of GCs per B cell follicle.
(A–H) Representative of at least four experiments with at least four animals per genotype per experiment. + SEM (C).
(I and J) Representative of sections from at least five animals of each genotype. Statistics conducted with Student’s unpaired t test. WT, wild-type (Stat3fl/fl
cre-negative) mice. See also Figure S1.
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STAT3 and Type I IFNs in Tfh Cell Differentiationobserved a decrease in the percentages of CD4+ CD44+
CXCR5hi IL-21 and IFN-g double producers (IL-21 IFN-g DP)
at 8 dpi (Figures 3C and 3D). This trend was shared with IL-21-single producers (IL-21 SP), but there was no difference in
IFN-g SP between Stat3fl/fl cre-negative WT and mutant mice
(Figures 3E and 3F).Immunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc. 369
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Figure 2. Stat3fl/flCd4cre (Stat3–/–) Mice Are
Hindered in their Ability to Create LCMV-
Specific Antibodies
(A and B) IgM and IgG anti-LCMV at 8 dpi.
(C–E) IgM, IgG, and IgG2a anti-LCMV at 14 dpi.
(A–E) Representative of at least two experiments
with at least four animals per genotype per
experiment. Statistics conducted using Student’s
unpaired t test. + SEM (A–D). See also Figure S2.
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STAT3 and Type I IFNs in Tfh Cell DifferentiationRepression of Tfh cell differentiation following viral infec-
tion has been shown to occur through IL-2-mediated STAT5
signaling via the high-affinity IL-2Ra chain (CD25), with promo-
tion of Blimp-1 expression and suppression of Bcl6 (Choi et al.,
2011; Johnston et al., 2012; Nurieva et al., 2012; Pepper et al.,
2011). Accompanying the decrease in Bcl6 in the STAT3-
deficient CD4+ T cells, we found increased CD25 expression at
5 dpi, a time at whichWTTfh cells normally turn down expression
of this receptor (Figures 3G and 3H). We also found an increase
in T-bet expression at this time point and at 14 dpi (Figures 3I and
3J; Figures S2I and S2J), with no difference at 8 dpi (data not
shown), in line with the increase in Th1 cell development. These
data show that STAT3 promotes Tfh cell differentiation in part by
inducing Bcl6 and suppressing T-bet and IL-2 signaling.
Gene-Expression Analysis Reveals a STAT1-Driven
Transcriptome in STAT3-Deficient Tfh Cells
Because STAT3-deficient Tfh cells had characteristics of Th1
cells, we next asked whether their global gene expression was
also consistent with that phenotype. Therefore, we performed
RNA-sequencing (RNA-seq) on sorted polyclonal CD4+CD44+
T cells from WT and STAT3-deficient CD4+ T cells, again by us-
ing Ly6c and PSGL-1 expression to distinguish the three effector
populations, with further gating on the CXCR5hi group within the
Ly6clo PSGL-1lo subset to distinguish Tfh cells (Figure 1A; Fig-
ure S1A). We used a multidimensional scaling plot to relate the
similarities and differences among the populations relative to
one another (Figure S3A), finding that Stat3fl/fl cre-negative WT
Tfh cells (Ly6clo PSGL-1lo CXCR5hi) had vastly different gene
expression than either their Th1 Ly6clo PSGL-1hi or Th1 Ly6chi
PSGL-1hi counterparts, validating their separation by surface
marker expression (Marshall et al., 2011). In addition, we used
unbiased K-means clustering to determine how global STAT3-
deficient Tfh cell gene expression compares to the three WT
populations (Figure 4A; Figure S3B). We found that STAT3-defi-
cient Tfh cells had a transcriptomemore similar to that of WT Th1
Ly6clo PSGL-1hi cells than the WT Tfh cells, as determined by
dendrogram (Figure 4A) and expression patterns (Figure 4A; Fig-
ure S3B). Integrated Pathway Analysis (IPA, Ingenuity Systems,
www.ingenuity.com) revealed that helper T cell differentiation
was the most deregulated pathway in STAT3-deficient Tfh cells370 Immunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc.with upregulation of genes associated
with T helper cell lineages such as regula-
tory T cells (i.e., Foxp3 and Il10) (Fig-
ure 4B; Figure S3C). To corroborate our
findings that STAT3-deficient Tfh cells
were phenotypically similar to Th1 cells,
we also found upregulated expression ofgenes associated with this lineage (i.e., Tbx21, Ifngr1, Il12r,
and Il2ra) (Figure 4B). In juxtaposition, six out of seven genes
with decreased expression in this canonical pathway were Tfh-
cell associated (Bcl6, Il21, Il4, Icos, Cxcr5, and Il6st) (Figure 4B).
In accordance with the downregulation ofBcl6 and other Tfh-cell
associated transcripts, we found an increase in Prdm1, which
encodes Blimp-1 (Figure 4C). We validated Bcl6, Il21, Il4, and
Prdm1 expression by qPCR (Figures S4A–S4D). Also in line
with our RNA-seq data, we observed an increase in Foxp3+
CD44+ Ly6clo CXCR5hi follicular regulatory T (Tfr) cells, with no
differences in GP66
+ Tfr cells at 8 dpi, although these cells
seem to be rather uncommon at this time point in LCMV infection
(Figures S4E and S4F).
STAT3-deficient Tfh cells also had a marked increase in RNA
expression of IFN-inducible genes over their WT littermates (Fig-
ure 4C), including transcripts downstream of both type I and type
II IFN signal transduction (Figure 4C; Figure S4G). We then deter-
mined potential upstream regulators by using IPA analysis,
finding that IFN regulatory factor-7 (IRF7) and STAT1 were the
top two transcription factors affiliated with the changes in gene
expression between STAT3-deficient versus WT Tfh cells (Table
S1). We also found suppressor of cytokine signaling-1 (SOCS1)
and SOCS3 phosphatase activity to be potentially decreased
in the STAT3-deficient Tfh cells based on the IPA analysis (Table
S1). As both SOCS1 and SOCS3 can act as repressors of STAT1
(Song and Shuai, 1998), an abundance of STAT1-mediated tran-
scription might occur due to this mechanism in the absence of
STAT3. However, SOCS1 and SOCS3 were not substantially
reduced in the absence of STAT3 according to our RNA-seq re-
sults (Figure 4C), and upon further analysis with qPCR, we found
that these mRNAs were actually upregulated in cells from
Stat3fl/flCd4cre animals (Figures S4H and S4I), a phenomenon
that might be due to an increase in type I IFN signaling. Similar
results were found upon repeating the RNA-seq analysis with
sorted cells with CD4+ CD44+ CXCR5hi PD-1hi gating strategy
(data not shown).
Type I IFN Signaling Aids in Th1 Cell Differentiation
In Vivo, at the Expense of that of Tfh Cells
Our RNA-seq data indicate that there is an increase in STAT1-
mediated transcription in the absence of STAT3. To determine
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Figure 3. Tfh Cells Deficient in STAT3 Are
Less Tfh-like Than Controls, with Charac-
teristics of Th1 Cells
(A and B) Flow cytometry plot (A) and quantifica-
tion (B) of Bcl6 protein expression in Ly6cloPSGL-
1loCXCR5hi cells at 5 dpi (WT black line,
Stat3fl/flCd4cre [Stat3/] shaded gray).
(C–F) Flow cytometry plots (C) and population
quantification (D–F) of IL-21 and IFN-g-ex-
pressing cells of the CD4+ CD44+ CXCR5hi
population at 8 dpi (SP, single positive; DP,
double positive).
(G and H) Flow cytometry plot (G) and quantifica-
tion (H) of CD25 protein expression in Ly6clo
PSGL-1lo CXCR5hi cells at 5 dpi.
(I and J) Flow cytometry plot (I) and quantification
(J) of T-bet expression in Ly6clo PSGL-1lo CXCR5hi
cells at 5 dpi.
(A–J) Representative of at least two experi-
ments, with at least three animals per genotype
per experiment. Statistics conducted with Stu-
dent’s unpaired t test. + SEM (A–D). See also
Figure S3.
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STAT3 and Type I IFNs in Tfh Cell Differentiationthe role of STAT1 in determining Tfh cell differentiation, we ob-
tained a validated STAT1 small hairpin RNA vector and retrovir-
ally transduced viral epitope GP66-specific SMARTA transgenic
(Stg) CD4+ T cells with it (Choi et al., 2013; Oxenius et al.,
1998), and in parallel, with a control vector. Upon transduction,
there was substantial silencing of STAT1 (79%, Figures S5A
and S5B), and a large reduction in clonal expansion of trans-
duced cells (Figure S5C). We found a slight but reproducible
reduction in T-bet expression after transfer into WT congenic
hosts (Figure S5D), which was not surprising given that STAT4
has also been shown to drive T-bet expression (Nakayamada
et al., 2011). Despite differences in clonal expansion, there
were no differences in Tfh cells or Bcl6 expression at 8 dpi (Fig-
ures S5E and S5F). It is possible that the use of TCR transgenic
T cells nullifies the Tfh cell phenotypes that would otherwise be
seen in a polyclonal repertoire (Tubo et al., 2013); however, in
line with our data analyzing the polyclonal population (Figures
1A and 1B), we found that STAT3-deficient Stg+ cells also had
a deficiency in the Tfh cell subset at 8 dpi (Figure S5G). Similar
to polyclonal STAT3-deficient T cells, they had no significant dif-
ferences in Bcl6 protein at 8 dpi (Figure S5H), but there was a
marked increase in T-bet expression (Figure S5I). Thus, despite
the increase in STAT1-mediated gene transcription in STAT3-
deficient T cells, Tfh cell phenotypes were modulated by spe-
cific STAT1 signaling cytokines in addition to general STAT1
signaling, because this transcription factor is also known to op-
erate downstream of Tfh-cell inducing cytokines (i.e., IL-6).
Our RNA-seq data suggested a role for both type I and type II
IFN signaling in promoting the changes in gene transcription we
observed (Figure S4G). Previous work has found that IFN-g in-
duces Tfh cell formation, and that in the absence of its receptor,
Roquinsan/san lupus-prone mice are rescued from their disease
phenotype with reductions in Tfh cell numbers, GCs, and forma-
tion of autoantibodies (Lee et al., 2012). To ascertain the effect of
IFN-g on Tfh cell differentiation in our model, we blocked this
cytokine by using the XMG1.2 neutralizing antibody (Abramset al., 1992). Despite a large reduction in splenocyte numbers
and T-bet expression upon IFN-g blockade (Figures S5J and
S5K), we found that there was only a marginal, and insignificant,
increase in Tfh cell percentages and Bcl6 expression at 8 dpi
(Figures S5L and S5M), without an effect on GC B cell percent-
ages (Figure S5N). Thus, despite its role in driving Tfh cells in
the Roquinsan/san autoimmunity model, IFN-g does not appear
to have a large effect on the differentiation of Tfh cells following
acute LCMV infection.
We then examined the effects of type I IFNs on Tfh cell differ-
entiation. Type I IFNs are induced following LCMV infection and
they regulate STAT1- and IRF7-mediated gene expression
(Malmgaard et al., 2002). To determine whether T cell-intrinsic
type I IFN signaling is responsible for suppressing Tfh cell forma-
tion in favor of Th1 cell differentiation, we crossed Ifnar1/mice
to Stg+ mice, and transferred Ifnar1/ Stg+ CD4+ T cells into
infected WT C57BL/6 animals. As previously described (Have-
nar-Daughton et al., 2006; Way et al., 2007), the expansion of
Ifnar1/ Stg+ CD4+ T cells was severely compromised at 8 dpi
(data not shown), indicating an effect on CD4+ T cell proliferation
and differentiation. In addition, there was an increase in the
percentages of Tfh cells along with increased Bcl6 protein,
compared to those mice given WT Stg+ cells, but with no effects
on T-bet expression (Figures 5A–5C; Figure S5O).
Given these findings, we wondered whether type I IFN
signaling could actively suppress Tfh cell differentiation, which
could potentially explain the propensity of Stat3fl/flCd4cre CD4+
T cells to develop a Th1-like phenotype. Indeed, upon type I
IFN treatment of LCMV epitope-stimulated Stg+ WT CD4+
T cells, there was an increase in expression of CD25 and phos-
pho-STAT5 (p-STAT5) downstream of IL-2 stimulation (Fig-
ure 5D). We found this effect to be dependent on IL-2 and
reversed upon treatment with an IL-2 blocking antibody (Fig-
ure 5E), suggesting that direct type I IFN signalingmight promote
IL-2 responsiveness and Th1 differentiation during viral infection
in vivo (Johnston et al., 2012; Nurieva et al., 2012; OestreichImmunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc. 371
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Figure 4. STAT3-Deficient Tfh Cells Have a
Th1-like Transcriptome
(A and B) Expression analysis of Ly6clo PSGL-1lo
CXCR5hi, Ly6clo PSGL-1hi, and Ly6chi PSGL-1hi
cells from Stat3fl/flCd4cre (Stat3/) and Stat3fl/fl
cre-negative (WT) mice. (A) Unbiased K-means
clustering and dendrogram based on differential
gene expression of the three WT populations (see
Figure S4B). The bar on the left denotes from
which cluster genes come based on Figure S4B.
The blue cluster is most associated with WT Tfh
cells, green with both WT Th1 cell (PSGL-1hi)
populations, and magenta with WT terminal
effector cells. Reduced expression is in green with
induced expression in red. (B) List of differentially
expressed genes from the IPA T helper cell dif-
ferentiation pathway, with those in red associated
with Th1 cells and those in green with Tfh cells.
(C) Tfh-cell associated and Th1 and IFN-inducible
genes upregulated in STAT3-deficient Tfh cells.
Fold changes listed as the ratio of Stat3fl/flCd4cre
(Stat3/) to WT Tfh cell expression. See also
Figure S4 and Table S1.
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STAT3 and Type I IFNs in Tfh Cell Differentiationet al., 2012). It is possible that T cells deficient in STAT3 are
more sensitive to type I IFN and IL-2 signaling, because this tran-
scription factor has been shown to suppress STAT5 signaling
(Oestreich et al., 2012). In accordance with this hypothesis,
STAT3-deficient cells had IL-2-dependent enhanced expression
of CD25 with peptide stimulation and IFN-b treatment compared
toWT cells (Figure 5E). STAT3 binding in theBcl6 locus occurs in
conditions with low IL-2, whereas high amounts of IL-2 allow
STAT5 to outcompete STAT3 for binding sites, hampering Bcl6
expression (Oestreich et al., 2012). To determine how type I
IFNs might affect STAT binding to the Bcl6 locus, we used
chromatin immunoprecipitation-qPCR (ChIP-qPCR) to deter-
mine binding of STAT1, STAT3, and STAT5 in the presence of
IL-6 or type I IFNs. We used previously confirmed (Bcl6 4) and
newly generated qPCR primer sets surrounding STAT-binding
sites (Figure 5F) (Oestreich et al., 2012). While STAT3 bound372 Immunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc.the Bcl6 locus in the presence of IL-6,
STAT5 bound robustly in the presence
of type I IFNs in all primer sets tested
(Figure 5G), with little binding of STAT1
in either context. This suggests that type
I IFN-induced IL-2 signaling leads to
STAT5 binding at the expense of STAT3.
Thus, in the absence of STAT3 following
acute viral infection, IL-2 and STAT5
signaling is likely dominant, leading to a
reduction in Tfh cell differentiation.
Type I IFN Blockade Partially
Rescues the Stat3fl/flCd4cre Tfh
Cell, GC B Cell, and Pathogen-
Specific Antibody Phenotypes
Although type I IFNs appear to insulate
against Tfh cell in favor of Th1 cell
differentiation during viral infection, we
hypothesized that this effect might beexacerbated in the absence of STAT3 signaling. To determine
whether blockade of type I IFNs could rescue the Tfh cell defect
in LCMV-infected mice bearing STAT3-deficient CD4+ T cells,
we used the MAR1-5A3 (MAR1) IFN-abR blocking antibody
(Sheehan et al., 2006). Unlike the Ifnar1/CD4+ T cells, pretreat-
ing WT and Stat3fl/flCd4cre mice with the MAR1 antibody at
a dosage of 600 mg per mouse did not compromise expansion
of CD44+ or GP66+ CD4+ T cells following viral challenge (data
not shown). Upon pretreatment with MAR1, Stat3fl/flCd4cre
mice and their WT littermates had substantial increases in Ly6clo
PSGL-1lo Tfh cells, as well as Ly6clo PSGL-1hi Th1 cells, while
there was a decrease in Ly6chi PSGL-1hi Th1 cells among both
GP66+ and total CD44+ cells (Figures 6A–6E; Figures S6A–
S6E). Notably, the Stat3fl/flCd4cre mice treated with MAR1 had
similar Ly6clo PSGL-1lo cell percentages to WT IgG treated
mice, suggesting that STAT3 and type I IFNs act as mutually
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Figure 5. Type I IFNs Inhibit Tfh Cell Differentiation
(A) Flow cytometry plots of Ifnar1+/+ and Ifnar1/ CD4+ CD44+ Stg+ cells gated on Ly6c and PSGL-1 at 8 dpi.
(B) Ly6c and PSGL-1 populations, gated as in (A).
(C) Bcl6 protein expression in Ifnar1+/+ and Ifnar1/ Stg+ cells.
(D) Flow cytometry plots of CD25 and p-STAT5 expression of WT Stg+ cells, either unstimulated (unstimmed) or stimulated with the cognate LCMV peptide GP61
for 4 days, or with this peptide + 10 ng IFN-b for 4 days. p-STAT5 samples were stimulated with IL-2 for 25 min prior to fixation.
(E) CD25 protein expression forWT and Stat3fl/flCd4cre (Stat3/) Stg+ T cells stimulated with the cognate LCMV peptide GP66 for 3 days, with this peptide + 10 ng
IFNb for 3 days, or with peptide, 10 ng IFN-b, and aIL-2.
(F) Schematic showing the location of primer sets (arrows) used to determine STAT binding in theBcl6 locus. Tic marks are 1 kb and indicate the distance from the
transcription start site.
(G) ChIP-qPCR of STAT1, STAT3, or STAT5 for STAT binding within the Bcl6 locus on WT Stg+ T cells treated with 10 ng/mL IL-6 or IFN-b.
(A–D) Representative of at least three experiments, with at least three animals per genotype per experiment.
(E and G) Representative of at least two experiments. Statistics conducted with Student’s unpaired t test or one-way ANOVA with Tukey posttest; *p% 0.05,
**p% 0.01, ***p% 0.001, ****p% 0.0001 (E). + SD (C and E). See also Figure S5.
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respectively (Figures 6A–6C; Figures S6A–S6C). The WT
MAR1-treated mice also had a remarkable increase in Tfh cells
beyond that of treated Stat3fl/flCd4cre mice, suggesting that
STAT3 might have direct effects on Tfh cell differentiation other
than insulating against type I IFNs. To corroborate these data,
we found at 8 dpi a significant increase in Bcl6 protein expres-
sion in both Stat3fl/flCd4cre and WT GP66
+ and total CD4+CD44+ T cells upon MAR1 treatment, compared to a lack of dif-
ferential expression between untreated Stat3fl/flCd4cre and WT
mice (Figure 6F; Figure S6F). CXCR5 expression was unaffected
upon treatment in GP66-specific T cells, although increased
among total WT CD44+ cells (Figure 6G; Figure S6G). We found
a repeatable, albeit insignificant, reduction in IFN-g production
upon MAR1 treatment (Figure 6H). The effects on IL-21, how-
ever, were more variable, with a possible increase in IL-21 SPImmunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc. 373
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Figure 6. Inhibition of Type I IFN Signaling
Partially Rescues STAT3-Deficient Tfh Cell
Phenotypes
(A and B) Flow cytometry plots of WT (A) or
Stat3fl/flCd4cre (Stat3/) (B) CD4+ CD44+ GP66
+
Ly6c and PSGL-1 expressing cells, with treatment
of the MAR1 blocking antibody or isotype control
(IgG).
(C–E) Comparisons of percentages of GP66
+ Ly6c
and PSGL-1 populations between isotype and
MAR1-treated WT and Stat3fl/flCd4cre (Stat3/)
mice, using the gating in (A).
(F) Bcl6 MFI of GP66
+ cells.
(G) CXCR5 MFI of GP66
+ Ly6clo PSGL-1lo cells.
(H) IFN-g SP cells gated on CD4+ CD44+ CXCR5+.
(I) GC B cell percentages gated on B220+ IgDlo
CD95+ GL-7+ cells.
(J and K) Serum concentrations of LCMV-specific
IgM (J) and IgG (K).
(A–K) Representative of two to three experiments,
with at least three animals per condition per
genotype. (J) and (K) are pooled from two separate
experiments, where serum concentrations were
normalized to WT IgG treated. Statistics con-
ducted with one-way ANOVA with Tukey posttest.
*p% 0.05, **p% 0.01, ***p% 0.001. + SEM (F–H).
See also Figure S6.
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(Figures S6H and S6I).
To analyze the downstream effect of increased Tfh cells in the
MAR1-treated mice, we studied GC B cell percentages and
pathogen-specific antibody responses. We found that, unlike
the effect on Tfh cells, MAR1 had a minimal effect on GC B cell
percentages in WT mice. However, in the animals containing
STAT3-deficient T cells, GC B cells were rescued toWT percent-
ages (Figure 6I). In line with this finding, whereas effects on IgM
were no different, pathogen-specific IgG antibody responses
were rescued to the concentrations of WT control animals (Fig-
ures 6J and K). This suggests that type I IFNs play an inhibitory
role in plasmablast and plasma cell responses in addition to de-
terring the GC response. We also found a moderate increase in
SOCS3 protein expression in the STAT3-deficient Tfh cells (Fig-
ure S6J), in agreement with our qPCR data (Figure S4I). This was
reduced by MAR1 treatment (Figure S6J), suggesting that type I
IFNs elicit the increase in SOCS3 expression found in the
Stat3fl/flCd4cre mutant.374 Immunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc.These data reveal a fine balance in
signaling pathways following acute viral
infection with a requirement for STAT3
for Tfh cell differentiation and type I IFNs
to promote that of the Th1 response.
DISCUSSION
We found that STAT3 is required for Tfh
cell differentiation and function during
acute viral infection. Mice with Tfh cells
that lack STAT3 display impaired GC
B cell and plasmablast formation leadingto the absence of antigen-specific antibody responses, with
promotion of Th1 cell differentiation mediated by type I IFN
signaling. Thus, there exists in vivo tight cytokine regulation of
Tfh versus Th1 cell differentiation.
STAT3 has been previously noted to aid in Tfh cell differentia-
tion following immunization with a nominal antigen (Nurieva et al.,
2008). In a like manner, it has been shown to make a transient
contribution to Tfh cell development following LCMV infection
(Choi et al., 2013), with the downstream effects of this process
in terms of GC responses consequently not analyzed (Choi
et al., 2013). However, we found a defect in the development
of STAT3-deficient polyclonal and Stg+ Tfh cells at day 8
following viral challenge, indicating that STAT3 affects Tfh cell
differentiation later than day 3. This earlier published work also
demonstrated that STAT1 aids STAT3 in transient promotion of
Tfh cell differentiation (Choi et al., 2013). Our finding that type I
IFNs perturb Tfh cell development in the absence of STAT3 sug-
gests that these cytokines utilize STAT1 in a cytokine-specific
manner in this process. Indeed, we did not see promotion of
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STAT1 can deter Tfh cell differentiation through signal transduc-
tion mediated by type I IFNs, it might also promote Tfh cell differ-
entiation through other cytokines (i.e., IL-6).
There are several possible mechanisms for type I IFN and
STAT3 cross-repression that can explain our findings, given
the complex regulatory network that involves competition for
binding partners, binding sites, and upregulation of repressive
SOCS proteins. For example, STAT3 has the capacity to bind
to the same consensus region as STAT1, potentially blocking
its transcription and vice versa (Wang et al., 2011). The N-termi-
nal domain of STAT3 also has been shown to inhibit type I IFN
signaling following viral infection of mouse embryonic fibroblasts
through sequestration of STAT1. However, we did not find pro-
motion of Tfh cell differentiation in STAT1-silenced Stg+ T cells
following viral infection. STAT3 and type I IFN cross regulation
also could occur via their respective downstream signaling
attenuators, SOCS1 and SOCS3. For example, in the absence
of STAT3, a lack of either could lead to an increase in STAT1
or STAT5 phosphorylation, reminiscent of that seen in CD8+
T cells in the absence of STAT3 (Cui et al., 2011). However,
this mechanism also seems unlikely, as we observe an increase
in the expression of SOCS1 and SOCS3 transcripts and SOCS3
protein expression in the Stat3fl/flCd4cre in a type I IFN-depen-
dent manner.
Another possible mechanism for type I IFN and STAT3 cross-
repression, and one apparent from our results, is through type I
IFN promotion of CD25 expression and subsequent STAT5
phosphorylation. In the absence of STAT3, CD25 expression is
increased, and upon stimulation of WT STg+ cells with their
cognate peptide and type I IFNs, its expression is also increased,
accompanied by enhanced p-STAT5, in an IL-2-dependent
manner. STAT5 competes with STAT3 for consensus DNA bind-
ing sites, including at the Bcl6 locus (Oestreich et al., 2012). We
found that STAT5 outcompeted STAT3 for binding at the Bcl6
locus in the presence of type I IFNs. STAT3-deficient Tfh cells
appear to have an increase in Blimp-1 expression, and STAT5
has also been shown to upregulate Blimp-1, potentially inhibiting
Tfh cell differentiation through cross-repression of Bcl6 and with
promotion of Th1 cell differentiation (Johnston et al., 2009, 2012;
Nurieva et al., 2012; Oestreich et al., 2012). Thus, increased IL-2
signaling via type I IFNs likely upregulates Blimp-1 and deters
Bcl6-mediated Tfh cell differentiation (Johnston et al., 2012; Nur-
ieva et al., 2012;Oestreich et al., 2012). In the presence of STAT3,
Tfh cell differentiation was promoted upon type I IFN blockade
during acute viral infection. Therefore, it is likely that STAT3 plays
multiple roles, one as an insulator against type I IFNs and another
as an enhancer of Tfh cell differentiation. Likewise, type I IFNs
might also play dual roles, by both promoting Th1 cell differenti-
ation through STAT1 induction of Tbx21 and Tfh cell differentia-
tion through upstream (or indirect) induction of autocrine IL-2,
subsequently leading to STAT5 activation and direct competition
with STAT3 for binding sites in the Bcl6 locus.
Patients with dominant-negative STAT3 mutations have char-
acteristic decreases in circulating ‘‘Tfh-like’’ cells in their blood,
as well as lower serum antigen-specific IgG concomitant with
increased IgE (Ma et al., 2012). Many of these patients suffer
recurrent infections from Candida albicans and Staphylococcus
aureus due to a scarcity of Th17 cells, with STAT3 signalingnecessary for the development of this subset (de Beaucoudrey
et al., 2008; Ma et al., 2008; Milner et al., 2008; Renner et al.,
2008). Given these findings and that such patients have defi-
ciencies in memory T cells, it is prudent to further characterize
the T and B cell intrinsic components of STAT3 signaling in
developing long term immunity. Patients with the autoimmune
syndrome systemic lupus erythematosus (SLE) have high titers
of autoantibodies and an abundance of Tfh cells (Craft, 2012);
thus, blockade of STAT3 signaling might be therapeutically
beneficial, with a decrease in T cell-mediated autoantibody pro-
duction. Although we show here that STAT3 plays a role in Tfh
cell differentiation in acute viral infection, this transcription factor
also is required for regulating Th2 type immunity (Stritesky et al.,
2011). We and others have shown that in the absence of STAT3,
there is a drastic reduction in IL-4 production, with STAT3 impor-
tant for opening the IL-4 locus to enable STAT6 binding (Stritesky
et al., 2011). In Th2 cell-associated infections, IL-4 production by
T cells is important for inducing antigen-specific IgE production
by plasma cells. Given the importance of STAT3 in promoting
Th2 cell type immunity, it will be critical to explore the effects
of CD4+ T cell STAT3 signaling in exacerbating allergic disease
such as asthma. STAT3 inhibitors are in development, and
this could be a useful therapeutic for those who suffer from
Tfh-cell mediated autoimmune diseases such as SLE, or
those with allergic illnesses, given the effect of STAT3 on IL-4
production.
EXPERIMENTAL PROCEDURES
Mice and LCVM Infection
Mice were housed in specific pathogen-free conditions at the Yale School
of Medicine (New Haven, CT). C57BL/6 (B6) mice were purchased from the
National Cancer Institute (Bethesda, MD), with other strains provided as noted:
Stat3fl/fl (B6.129S1-Stat3tm1Xyfu/J) mice from Xin-Yuan Fu at the Indiana
University School of Medicine, Cd4cre (B6.Cg-Tg(Cd4-cre)1Cwi/BfluJ) from
Christopher Wilson at the University of Washington in Seattle, SMARTA Tg
(Tg(TcrLCMV)1Aox) from Hans Hengartner at the University of Zu¨rich in
Switzerland, and Ifnar1/ (Ifnar1tm1Agt) from Michel Aguet at the University
of Zu¨rich in Switzerland. All were used at 6–8 weeks of age. The Institutional
Animal Care and Use Committee of Yale University approved all procedures
involving mice. They were infected with LCMV Armstrong by intraperitoneal
(i.p.) injection of 2 3 105 PFU per mouse.
Antibodies for Flow Cytometry and Cell Sorting
These protocols are described in detail in the Supplemental Experimental
Procedures.
Microscopy
These protocols are described in detail in the Supplemental Experimental
Procedures.
ELISA for Antibodies to LCMV
Anti-LCMV Ab was measured by ELISA with sonicated cell lysate from LCMV-
infected BHK-21 cells as capture Ag. Ninety-six-well Polysorpmicrotiter plates
(Nunc) were coated overnight with lysate in PBS. AP-conjugated goat anti-
mouse IgM, IgG, and IgG2a secondary Abs were used for detection (Southern
Biotech). ODswere converted to units basedon standard curveswith sera from
WT mice infected with LCMV (Softmax Pro 3.1 software; Molecular Devices).
RNA-Seq
Sorted Tfh cells were lysed with their RNAs isolated with the miRNeasy kit
(QIAGEN). Samples were sequenced on an Illumina HiSeq 2000 with 75-bp
paired-end reads. FASTQ format sequencing reads were aligned to the
MM9 mouse genome using TopHat version 2.0.6 and Bowtie version 1.3.0.Immunity 40, 367–377, March 20, 2014 ª2014 Elsevier Inc. 375
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maps were made with CummeRbund version 2.0.0. Quantitative real-time
PCR was used to confirm expression of RNA transcripts. IPA Ingenuity Sys-
tems was used to analyze deregulated pathways and potential upstream
regulators.
Quantitative PCR
These protocols are described in detail in the Supplemental Experimental
Procedures.
Retroviral Transduction and Cell Transfer
These protocols are described in detail in the Supplemental Experimental
Procedures.
Immunoblot
These protocols are described in detail in the Supplemental Experimental
Procedures.
Chromatin Immunoprecipitation
These protocols are described in detail in the Supplemental Experimental
Procedures.
Type I IFN, IFN-g, and IL-2 Blockade
For type I IFN blockade,WT or Stat3fl/flCd4cre mice were treated at day1with
600 mg of MAR1-5A3 IFN-abR blocking antibody or IgG1 isotype control anti-
body (both from Leinco Technologies) in PBS via i.p. injection (Sheehan et al.,
2006), before infection with LCMVArmstrong at day 0. For IFN-g blockade,WT
mice were treated at day 0 and day 3 after LCMV Armstrong infection with
250 mg of XMG1.2 IFN-g blocking antibody or PBS vehicle control (Abrams
et al., 1992). IL-2 blocking antibody (JES6-1A12) was used in vitro at a concen-
tration of 10 mg/mL (Abrams et al., 1992).
Statistics
Data were analyzed with the Student’s unpaired t test or with one-way ANOVA
with Tukey posttest for multiple comparisons with Prism 6. The number of as-
terisks represents the degree of significancewith respect to p values, and the p
value is presented within each figure or figure legend.
ACCESSION NUMBERS
The GEO accession number for the RNA-Seq data reported in this paper is
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